Biopharmaceutical reports 6/8

Samsung RA Biosimilar EU Uptake Tied to Perceived Cost Despite Physician Concerns

• Reference companies may lower drug prices too • Payers may mandate biosimilar use in tender markets • Immunogenicity reactions...

Controlling Drug Prices

Biopharmaceutical Report III Goodwill Hunting Martin Shkreli and Hillary Clinton last week provided the flint and steel that ignited a...

AbbVie’s Combination Drug for Hepatitis C has Elicited Mixed Expert Opinions

• Success in vitro foreshadows pan-genotypic success • Six HCV genotypes have unique viral dynamics • Drug should be bearable for...

No Differentiation Expected Among PARP Inhibitors

PARP inhibitors like Tesaro’s (NASDAQ:TSRO) niraparib, Clovis Oncology’s (NASDAQ:CLVS) rucaparib and AstraZeneca’s (LON:AZN) approved...

RULES OF COMPETITION

Competing in gene therapy is unlikely to follow the same rules as competing in other therapeutic categories where — even in Orphan...

Seattle Genetics/Takeda’s Adcetris, likely to get label expansion

Seattle Genetics (NASDAQ:SGEN) and Takeda Pharmaceutical’s (TYO:4502) Adcetris (brentuximab vedotin) will likely get a Hodgkin’s lymphoma...

US Rheumatologists’ View on Biosimilars

Rheumatologists in the US eagerly anticipate biosimilars for pricey anti-TNFs and other biologics used to treat rheumatic diseases but...

Anlysis of Bio - Pharma in East Asia - Trends Report

Featured Story of Korean Pharma: Hanwha confirms abandoning bid for Dow Chemical basic chemical units Hanwha Corp is no longer seeking to...

Astellas/Medivation's Xtandi Has Questionable Potential to Displace Bicalutamide

Astellas (TYO:4503)/Medivation's (NASDAQ:MDVN) Phase II TERRAIN study topline data on Xtandi has left experts questioning whether it will...

Spark's LCA2 gene therapy is likely to have greater benefit for younger patients

Spark Therapeutics' (NASDAQ:ONCE) subretinal gene therapy injection of SPK-RPE65, is likely to restore vision most effectively in younger...

Subscribe to Our Journal